Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF HEMATOLOGY
Volume 90, Issue 8, Pages 739-745
Publisher
Wiley
Online
2015-06-24
DOI
10.1002/ajh.24094
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma
- (2015) Tadeusz Robak et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase 1 study of the PI3K inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)
- (2014) B. S. Kahl et al. BLOOD
- Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study
- (2014) I. W. Flinn et al. BLOOD
- A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213
- (2013) S. H. Bernstein et al. ANNALS OF ONCOLOGY
- Combination of Rituximab, Bendamustine, and Cytarabine for Patients With Mantle-Cell Non-Hodgkin Lymphoma Ineligible for Intensive Regimens or Autologous Transplantation
- (2013) Carlo Visco et al. JOURNAL OF CLINICAL ONCOLOGY
- Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
- (2013) Mathias J Rummel et al. LANCET
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- (2013) Michael L. Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database
- (2012) A. S. LaCasce et al. BLOOD
- CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte
- (2012) R. Delarue et al. BLOOD
- Molecular pathogenesis of mantle cell lymphoma
- (2012) Pedro Jares et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90–Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499
- (2012) Mitchell R. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
- (2012) Michael Wang et al. LANCET ONCOLOGY
- Treatment of Older Patients with Mantle-Cell Lymphoma
- (2012) H.C. Kluin-Nelemans et al. NEW ENGLAND JOURNAL OF MEDICINE
- The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma
- (2011) J. W. Friedberg et al. BLOOD
- Mantle Cell Lymphoma International Prognostic Index but Not Pretransplantation Induction Regimen Predicts Survival for Patients With Mantle-Cell Lymphoma Receiving High-Dose Therapy and Autologous Stem-Cell Transplantation
- (2011) Lihua E. Budde et al. JOURNAL OF CLINICAL ONCOLOGY
- Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era
- (2010) P. Perez-Galan et al. BLOOD
- Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma
- (2010) V. Fernandez et al. CANCER RESEARCH
- A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
- (2010) T E Witzig et al. LEUKEMIA
- Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma
- (2009) C. S. Tam et al. BLOOD
- How I treat mantle cell lymphoma
- (2009) M. Ghielmini et al. BLOOD
- The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)
- (2009) C. H. Geisler et al. BLOOD
- Phase II Study of Yttrium-90–Ibritumomab Tiuxetan in Patients With Relapsed or Refractory Mantle Cell Lymphoma
- (2009) Michael Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma
- (2009) Peter Martin et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- (2009) Georg Hess et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study
- (2008) A. Goy et al. ANNALS OF ONCOLOGY
- Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
- (2008) C. H. Geisler et al. BLOOD
- Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma
- (2008) Stephen M. Ansell et al. CANCER
- Five-Gene Model to Predict Survival in Mantle-Cell Lymphoma Using Frozen or Formalin-Fixed, Paraffin-Embedded Tissue
- (2008) Elena Hartmann et al. JOURNAL OF CLINICAL ONCOLOGY
- A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
- (2007) E. Hoster et al. BLOOD
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now